| GTO ID | GTC2195 |
| Trial ID | NCT04102436 |
| Disease | Lung Non-Small Cell Carcinoma | Ovarian Cancer | Genitourinary Cancer | Breast Cancer |
| Altered gene | Neoantigen |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | Neoantigen TCR-T cells |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer |
| Year | 2019 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 190143|19-C-0143 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||